Linkage and mutation analysis in an extended family with Charcot-Marie-Tooth disease type 1B

Eva Nelis, Vincent Timmerman, Peter De Jonghe, Ludo Muylle, Jean-Jacques Martin, Christine Van Broeckhoven

Abstract
Charcot-Marie-Tooth disease type 1 (CMT1) or hereditary motor and sensory neuropathy type I (HMSN) is an autosomal dominant peripheral neuropathy. In most families the disease segregates with a 1.5 Mb duplication on chromosome 17p11.2 (CMT1A). A few patients have been found with point mutations in the PMP-22 gene. In some families linkage has been found with markers located on chromosome 1q21-q25 (CMT1B) and more recently mutations have been identified in the P0 gene.

We analysed an extended CMT1 pedigree (CMT-B) without the CMT1A duplication. Significant positive linkage with chromosome 1 indicated that this family is of the CMT1B subtype. Sequencing of the candidate gene P0 located in chromosome band 1q21-q23 showed a C to A point mutation at position 446 in exon 3 resulting in an Asp134Glu substitution. Since the P0 mutation cosegregated with CMT1 disease we suggest that this mutation is the primary genetic cause of CMT1B in family CMT-B.

The hereditary motor and sensory neuropathies (HMSN) include clinically and genetically heterogeneous disorders of the peripheral nervous system. The prevalence of all HMSN forms is estimated as 1 in 10 000.2 HMSN type I or Charcot-Marie-Tooth disease type 1 (CMT1) is the most common form, characterised by progressive atrophy and paresis of distal limb muscles, depressed or absent deep tendon reflexes, and pes cavus deformity. The disease is mostly inherited as an autosomal dominant trait. The major electrophysiological and neuropathological features of CMT1 are nerve conduction velocities (NCV) of the median motor nerve below 38 m/s, and segmental de- and remyelination with onion bulb formations on peripheral nerve biopsy.

In the majority of CMT1 families designated CMT1A, the disease cosegregates with a 1.5 Mb duplication on chromosome 17p11.2-3 comprising the peripheral myelin protein 22 (PMP-22) gene.4 A few CMT1A patients have a single base mutation in the PMP-22 gene, proving that PMP-22 is involved in CMT1 pathogenesis.5-7

A minor CMT1B locus has been located on chromosome 1q, close to the Duffy blood group (FY) locus and the FcyRII gene.8-9 The major peripheral myelin protein P0 gene has been mapped to mouse chromosome 1q21-q23.10 Mutations of the P0 gene have been observed recently in CMT1 patients identifying the P0 gene as the CMT1B gene.5-13

Methods
MARKER ANALYSIS
Restriction fragment length polymorphisms (RFLPs) were recognised by the following chromosome 17p11.2 DNA markers: pEW301 (D17S58), pA10-41 (D17S71), pVAW409R3a (D17S22), pVAW409R1b (D17S122), pVAW412R3HeC (D17S125), pEW401 (D17S61), pEW503 (D17S67), and pVAW410R1 (D17S123). The chromosome 1q21-q23 DNA markers used were 3021 E1 (SPTA), PUM24P (PUM), 16.2pCD (FGC2), and pAG2 (AT3). The restriction fragment length polymorphisms (RFLPs) are described in detail in Genome Data Base (GDB). All manipulations, including isolation of genomic and plasmid DNA, digestion with restriction enzymes, Southern blot transfer of genomic DNA, and hybridisation with radiolabelled plasmid DNA were done according to standard procedures.

The Duffy blood group (FY) phenotypes were determined as described elsewhere.14

LINKAGE ANALYSIS
Two and multipoint lod scores were calculated respectively with the programs MLINK and LINKMAP of the LINKAGE computer package, version 5-1.15 Complete penetrance, autosomal dominant inheritance, and a gene frequency of 0-0001 was defined for the CMT1 phenotype. Equal male and female recombination rates were assumed. Multipoint recombination distances between the markers were obtained from Wright et al.16 for chromosome 17 and Lebo et al.17 for chromosome 1. Allele frequencies for the markers FCG2 and RM11-GT were obtained from seven married persons from the CMT-B family. In-
formation on allele and haplotype frequencies for all other markers were obtained from GDB.

MUTATION ANALYSIS

Manual and automated sequencing was performed. Part of the coding region of the P<sub>0</sub> gene was amplified by standard PCR using primers based on exon sequences. Two primer sets were used: one for amplification of the sequence between exons 2 and 3 (length of PCR fragment: 550 bp), that is, P<sub>0</sub>ex2F (5'-GGCCATCGTGGTATACCC-3')/P<sub>0</sub>ex3R (5'-GTTGTTCCTCCCTGACATG-3') and one for amplification of the sequence between exons 3 and 6 (length of PCR fragment: 1000 bp), that is, P<sub>0</sub>ex3F (5'-CCACTTGCCAAGGACAC-3')/P<sub>0</sub>ex6R (5'-CTGATTGCCTCTGAGG-3'). For sequencing we used the same primers or internal primers of exon 4 (P<sub>0</sub>ex4R 5'-CTGAGCCTCCTCTGAGG-3') and exon 5 (P<sub>0</sub>ex5F 5'-GGGAAATTGCACAAGCC-3'; P<sub>0</sub>ex5R 5'-GCTTCGAGCGGTTCCTTTTCCT-3'). Intronic primers were used to complete the sequencing of exon 3 (P<sub>0</sub>ex3-P4 5'-TCATTAGGTTCTCTACATGC-3'; P<sub>0</sub>ex3-M21 5'-GGCTGAATAAAGGTCCTTAGGC-3'), exon 5 (P<sub>0</sub>ex5-P6 5'-GAGAGGAGAAGCTGTTGCGGC-3'; P<sub>0</sub>ex5-M5 5'-CACATCAGTCACCGAGCGGAGATC-3'), and exon 6 (P<sub>0</sub>ex6-P41 5'-AGTTCGACTGGTGACTTGAT-3'; P<sub>0</sub>ex6-M46 5'-TAGTCATTCGATGACCA-3'). For manual sequencing we used a biotinylated primer in the PCR amplification and the PCR product was bound to streptavidin coated magnetic beads. After denaturation the single stranded DNA was sequenced using the dideoxy method. For automated sequencing we used the Prism Sequenase Terminator Double Stranded Sequencing Kit (Applied Biosystems). Electrophoresis and analysis was performed on a 373A DNA sequencer (Applied Biosystems).

Single strand conformational polymorphism (SSCP) analysis was performed by amplification of exon 3 of P<sub>0</sub> using the intronic primer set P<sub>0</sub>ex3-P4/P<sub>0</sub>ex3-M21. Standard polymerase chain reactions were carried out in the presence of [α-<sup>32</sup>P]dCTP. Samples were subjected to electrophoresis on a 1× HydroLink MDE (J T Baker) gel at 45 W for 330 minutes at 4°C.

Results

FAMILY CMT-B

Since the finding of the 1.5 Mb duplication in CMT1A patients we have tested a large number of CMT1 families for the presence of the CMT1A duplication using Southern blot hybridisation of MspI digested DNA with probes pVAW409R3a, pVAV412HBe, and pEW401HBe<sup>13</sup> and of FspI digested DNA with probe pVAW409R3a.<sup>14</sup> In 14 (82.5%) out of 17 CMT1 families the CMT1A duplication was present.<sup>17</sup> In all CMT1 families analysed, the clinical picture of the patients was consistent with a CMT1 phenotype according to the diagnostic criteria agreed upon by the European CMT consortium group,<sup>20</sup> that is, patients had slowly progressive symmetrical muscle atrophy and weakness, severely decreased motor nerve conduction velocity (median NCV <30 m/s), and absence or marked decrease of sensory nerve action potentials in the lower limbs. In only one of the three non-duplicated CMT1 families (family CMT-B) was the pedigree size sufficient for linkage analysis studies. The pedigree of family CMT-B consisted of five generations comprising 75 persons of whom 18 were clinically affected. The pattern of inheritance of the disease was autosomal dominant. Most patients had NCVs measured in the motor median nerve giving a mean value of 13.1 m/s (SD 3.3). The proband had a sensory nerve biopsy consistent with a diagnosis of demyelinating neuropathy. Blood samples for DNA analysis were obtained from 29 family members of family CMT-B (171). All patients and at risk persons in generations III to V had a neurological examination. Most patients had an electrophysiological examination to confirm their disease status while only one asymptomatic at risk person (IV.17) had NCVs measured that were normal.

LINKAGE ANALYSIS

Linkage analysis was performed in family CMT-B using RFLP and CA repeat markers located on chromosomes 17p11.2-p12 and 1q22-q25. Two point lod scores were calculated for the disease and are shown in the table. Recombinants were observed with the chromosome 17 markers D17S58, D17S71, and D17S123 located outside the CMT1A region as well as with D17S122 located inside the CMT1A duplication. Positive but non-significant lod scores were obtained with the markers D17S122, D17S125, and D17S61, all patients in the CMT1A duplication. In contrast, most of the chromosome 1 markers gave positive lod scores in the absence of recombinants. Conclusive two point lod scores were reached with the markers FCG2 and APOA2 suggesting that family CMT-B is a CMT1B family.

This was essentially confirmed by the multipoint linkage analyses of chromosomes 17p11.2 and 1q22-25 markers. The multipoint lod scores obtained with the markers D17S58, D17S122, and D17S123 exclude linkage of the disease in family CMT-B to the CMT1A region with an exclusion distance of 17.5 cM spanning the CMT1A duplication. The multipoint lod scores obtained with the markers SPTA, SFY, FCG2, and AT3 confirm linkage of the disease in family CMT-B to the CMT1B region with a maximum lod score of 4.85 at the FCG2 locus.

SEQUENCE ANALYSIS OF P<sub>0</sub> IN CMT-B

Since it was shown that the major peripheral myelin protein P<sub>0</sub> gene is located on mouse chromosome 1 in a region syntenic to the region of human chromosome 1 comprising the CMT1B region, we decided to perform a sequence analysis of this gene in patients of...
family CMT-B. Unfortunately no frozen nerve biopsy material of the proband was available. Also, at that moment only the human cDNA sequence of P0 was known. Therefore, we had to use genomic DNA for direct PCR sequencing using primers designed on the basis of the cDNA sequence of the human P0 gene. In rat and mouse the genomic organisation of the P0 gene was known, showing the intron/exon boundaries of six exons coding for P0. Using this information we deduced the location of the exonic sequences in the human cDNA sequence of P0 assuming that human P0 is also coded for by six exons. Two primer sets were designed based on the sequence of exons 2 and 3 and exons 3 and 6 respectively to amplify the genomic DNA of two affected and two unaffected subjects from family CMT-B. Subsequently the sequence of exons 2 to 6 was determined using either the primers used in the PCR amplification or internal primers designed based on the sequence of exons 4 and 5. Also, intronic sequence information obtained during the sequencing analysis was used to design additional primers. We were able to determine the complete coding sequence of exons 3, 4, 5, and 6 as well as the sequence of introns 3, 4, and 5 (the nucleotide sequence data will appear in the EMBL, GenBank, and DDBJ Nucleotide Sequence Databases under the accession numbers U10017 and U10018). The location of the intron/exon boundaries is in good agreement with that in the rat and mouse genomic sequences. In the patients’ DNA a C to A base change in exon 3 at position 446 was observed (fig 2A), resulting in an amino acid substitution at codon 134 changing an Asp to a Glu (codon numbering according to Hayasaka et al). The patients were heterozygous for the Asp134Glu mutation showing both the normal and the mutant allele. Compared to the published human cDNA sequence, a silent homozygous mutation of G to A was also detected in exon 2 at codon 72 coding for Gly.

SEGREGATION ANALYSIS OF P0 IN CMT-B

Next we examined the segregation of the exon 3 mutation in family CMT-B. Since the mutation did not alter a restriction recognition site, we analysed segregation using SSCP analysis. All 15 patients showed an altered mobility of the exon 3 PCR fragments (fig 2B). Two at risk subjects in generation II who had no neurological or electrophysiological examination also had the altered SSCP pattern indicating that they are carrying the mutation. Subject II.4 was affected according to family informants. The two other subjects (II.7 and II.12) are obligatory carriers of the disease. None of the at risk persons who were clinically unaffected based on their neurological ex-

Figure 1 Linkage pedigree of family CMT-B affected with autosomal dominant CMT1. Pedigree numbers refer to the position of the persons in the complete pedigree.
Discussion
We performed linkage and mutation analyses in an extended CMT1 pedigree, CMT-B, in which the disease segregates according to an autosomal dominant pattern. No CMT1A duplication was observed with markers for the CMT1A region. The negative lod scores with DNA markers in the 17p11.2 region excluded the CMT1A locus as the disease region in family CMT-B. These findings were confirmed by the fact that a mutation analysis of the PMP-22 gene was negative in family CMT-B (data not shown). With the chromosome 1q21-q25 markers, the positive lod scores were obtained indicating that family CMT-B is of the CMT1B subtype.

The major structural peripheral myelin protein zero, P0, is localised in the 1q21-q23 region and is a candidate gene for CMT1B. We established the sequence of the P0 gene by direct PCR sequencing in genomic DNA of patients and unaffected subjects of family CMT-B. In exon 3, a C to A mutation was detected at position 446 leading to an amino acid substitution of Asp by Glu at codon 134. The Asp134 codon is conserved among many species, such as mouse, rat, and bovine. SSCP analysis showed that all affected subjects of the family were mutated, while the married in and clinically unaffected at risk persons were not mutated. Also, the mutation was not present in 30 unrelated controls. These findings suggest that CMT1B disease in this family is caused by the amino acid substitution Asp134Glu within the extracellular domain of P0.

A silent homozygous mutation observed in exon 2 of all affected and unaffected CMT-B family members was observed, indicating no relationship with the disease. The same mutation was also found by others and thus most likely represents a non-pathological polymorphism.

Five distinct single base mutations in P0 resulting in an amino acid substitution have been identified in CMT1 patients using genomic DNA sequencing: Arg98His, Tyr82Cys, Lys96Glu, Asp90Glu, and Ile30Met. In one CMT1B family cDNA sequencing identified a 3 bp deletion present in all affected persons, resulting in a Ser deletion at codon 63. All these P0 mutations as well as the Asp134Glu mutation identified in this study are located in exons 2 or 3, coding for the extracellular domain of P0. The extracellular domain consists of a variable-like immunoglobulin (Ig) domain. This domain has been hypothesised to play a role in the compaction of myelin by homophilic interaction. It is not yet known how the P0 mutations influence the P0 functioning. It is possible that the mutations affect the homophilic interaction and therefore disturb myelin formation. Another possibility is that the mutated P0 protein is not properly inserted in the Schwann cell membrane, and that when remaining intracellular it is metabolically toxic.

CMT type 1 is a genetically heterogeneous disorder. Besides a common duplication on chromosome 17p11.2, a few point mutations in the PMP-22 gene, located in the CMT1A...
region, have been described. On chromosome 1, seven different mutations in the P0 gene have been found in CMT1 patients so far. Thus, CMT1 patients who are not duplicated for the CMT1A region should be screened for mutations in the P0, as well as in the PMP-22 gene to establish DNA diagnosis. CMT1 patients without CMT1A duplication or mutations in P0 or PMP-22 should be tested for mutations in other candidate genes for peripheral neuropathies. Recently, the mutations in the X chromosome Xq13.1 has been identified as the site of mutations in dominant X linked CMT1 families (CMTX). Therefore, in CMT1 patients in whom X linkage cannot be excluded, mutations in the Xq32 gene can also be sought.

The authors are grateful to all family members who cooperated in the research work. The authors would also like to thank G De Winter and G Smeyers for their help in contacting and informing the family and J De Voecht for technical assistance. This work was funded in part by a grant from the National Fund for Scientific Research (NFSR), the Concerted Action of the Flemish Ministry of Education, the Flemish Biotechnology Program of the Ministry of Economy, and Innogetics Inc., Gent, Belgium. VT is a research assistant and CVB is a research associated of the NFSR, Belgium.